Purine Metabolism Disorders and Hyperuricemia Research: Metabolic Pathways, Key Enzymes, and Detection Indicators
Purine Metabolism Disorders and Hyperuricemia Research: Metabolic Pathways, Key Enzymes, and Detection Indicators
Purine metabolism disorders and hyperuricemia research are mainly used to analyze increased uric acid production, reduced uric acid excretion, changes in xanthine oxidoreductase activity, and inflammatory responses induced by urate crystals. Experimental design should distinguish purine substrate accumulation, uric acid production rate, renal/intestinal transport abnormalities, and monosodium urate crystal effects.
Keywords: purine metabolism; hyperuricemia; uric acid detection; xanthine oxidase; urate crystals; uric acid transport; gout inflammation
1 Basic Positioning of Purine Metabolism Disorders and Hyperuricemia Research
1.1 Main Stages in Hyperuricemia Formation
(1) Increased uric acid production
When purine nucleotides, purine bases, and nucleosides undergo enhanced degradation, hypoxanthine and xanthine are further converted into uric acid. Cell damage, accelerated nucleic acid turnover, increased ATP consumption, elevated exogenous purine load, or increased xanthine oxidase activity may all increase the rate of uric acid production.
(2) Reduced uric acid excretion
Uric acid is mainly excreted through the kidneys, with partial elimination through the intestine. Transporters such as URAT1, GLUT9, OAT1/OAT3, and ABCG2 affect uric acid reabsorption, secretion, and efflux. In research, “overproduction” and “underexcretion” should be distinguished; otherwise, intervention targets may be misinterpreted.
(3) Urate crystal effects
When uric acid concentration, pH, ionic strength, and local microenvironment change, uric acid can form monosodium urate crystals. At this stage, the research focus is no longer limited to uric acid concentration, but also includes crystal formation, macrophage phagocytosis, NLRP3 inflammasome activation, and IL-1β release.
1.2 Common Research Questions
Purine metabolism disorder studies usually focus on three levels: whether upstream purine substrates increase; whether xanthine oxidase/xanthine dehydrogenase promotes uric acid production; and whether uric acid transport and urate crystal formation amplify tissue injury. Uric acid content in serum or culture supernatant only reflects endpoint changes. To explain mechanisms, xanthine, hypoxanthine, enzyme activity, transporters, and inflammatory indicators should also be analyzed together.
Table 1 Common Research Objects in Purine Metabolism Disorders and Hyperuricemia Studies
Research object | Main detection content | Research purpose | Recommended detection method |
Serum/plasma | Uric acid, xanthine, hypoxanthine | Evaluate hyperuricemia status and purine degradation level | Enzymatic assay, HPLC, LC-MS/MS |
Urine | Uric acid, creatinine, uric acid excretion | Assess uric acid excretion capacity and renal handling status | Uricase method, HPLC, creatinine correction |
Hepatocytes/liver tissue | XO/XDH activity, uric acid production | Analyze changes at the uric acid production end | Enzyme activity assay, Western blot, qPCR |
Kidney model | URAT1, GLUT9, OAT, ABCG2 | Study uric acid reabsorption, secretion, and efflux | Transporter detection, cellular uptake/efflux assay |
Inflammatory cells | MSU crystals, IL-1β, NLRP3 | Analyze urate crystal-induced inflammation | Crystal stimulation, ELISA, immunoblotting |
Drug intervention model | Uric acid, XO activity, transporter expression | Evaluate uric acid-lowering or mechanistic intervention direction | Biochemical assay, enzyme activity assay, molecular detection |
2 Purine Metabolic Pathway and Uric Acid Production Mechanism
2.1 Purine Nucleotide Synthesis and Salvage Pathways
(1) De novo synthesis
Purine de novo synthesis starts from PRPP and gradually forms IMP, which is then converted into AMP and GMP. This pathway is closely related to cell proliferation, nucleic acid synthesis, and energy metabolism. If nucleotide synthesis and degradation turnover are both enhanced, downstream purine degradation pressure may increase.
(2) Salvage pathway
Salvage enzymes such as HGPRT and APRT can convert free purine bases back into nucleotides, thereby reducing the entry of purines into the degradation pathway. When the salvage pathway becomes inefficient, hypoxanthine, guanine, and related purines are more likely to enter the uric acid production pathway.
2.2 Purine Degradation to Uric Acid
AMP and GMP can enter the uric acid production pathway through nucleosides, bases, and xanthine intermediates. Adenosine can be converted into inosine by adenosine deaminase, and inosine is further converted into hypoxanthine. Guanosine can generate guanine, which is then deaminated into xanthine. Hypoxanthine is converted into xanthine by xanthine oxidoreductase, and xanthine is further converted into uric acid. This stage is the most commonly intervened and detected production-side pathway in hyperuricemia research.
Table 2 Key Nodes in the Purine Degradation Pathway
Metabolic node | Upstream source | Downstream fate | Research significance |
Adenosine | AMP degradation | Inosine | Reflects adenine nucleotide degradation |
Inosine | Adenosine deamination | Hypoxanthine | Connects adenosine metabolism with uric acid production |
Hypoxanthine | Inosine cleavage, salvage pathway imbalance | Xanthine | Substrate of XO/XDH reaction |
Xanthine | Hypoxanthine oxidation, guanine deamination | Uric acid | Precursor of uric acid production |
Uric acid | Xanthine oxidation | Excretion or crystallization | Core endpoint of hyperuricemia detection |
Monosodium urate crystals | Uric acid supersaturation | Inflammatory stimulation | Model for gout and crystal-induced inflammation |
2.3 Role of Xanthine Oxidoreductase
Xanthine oxidoreductase includes two functional states: xanthine dehydrogenase and xanthine oxidase. The former mainly uses NAD⁺ as the electron acceptor, whereas the latter can use oxygen as the electron acceptor and generate reactive oxygen species. In hyperuricemia research, xanthine oxidase not only affects uric acid production but may also participate in oxidative stress. Therefore, measuring uric acid content alone is insufficient to explain changes in enzyme activity; xanthine oxidase activity, reactive oxygen species levels, and related protein expression are usually analyzed together.
3 Mechanistic Research Directions Related to Hyperuricemia
3.1 Abnormalities at the Uric Acid Production End
(1) Increased purine substrates
Enhanced nucleic acid degradation, cell lysis, increased ATP consumption, or elevated purine intake can all increase the supply of hypoxanthine and xanthine. In experiments, uric acid, xanthine, and hypoxanthine can be detected simultaneously to determine whether elevated uric acid originates from increased upstream substrates.
(2) Increased xanthine oxidase activity
Elevated xanthine oxidase activity promotes uric acid production and may be accompanied by increased oxidative stress. If uric acid decreases after intervention but xanthine or hypoxanthine accumulates significantly, the intervention may mainly act on the XO reaction step.
3.2 Abnormalities at the Uric Acid Excretion End
Uric acid transport involves renal tubular reabsorption, secretion, and intestinal efflux. URAT1 and GLUT9 are often associated with uric acid reabsorption, OAT1/OAT3 participate in organic anion transport, and ABCG2 is closely related to uric acid efflux and intestinal excretion. When studying excretion-side abnormalities, blood uric acid changes should not be evaluated alone; urinary uric acid, uric acid clearance, creatinine-corrected values, and transporter expression should also be included.
3.3 Urate Crystals and Inflammatory Responses
Monosodium urate crystals can be recognized and phagocytosed by macrophages and other immune cells, inducing inflammasome activation and IL-1β release. This model is suitable for studying crystal inflammation, immunometabolism, and anti-inflammatory interventions, but it is not equivalent to a simple hyperuricemia model. If the research target is the “hyperuricemia state,” uric acid concentration and metabolic pathways should be emphasized. If the research target is “urate crystal inflammation,” crystal preparation, particle size, endotoxin-free treatment, and cellular stimulation conditions should be carefully controlled.
Table 3 Mechanistic Stratification in Hyperuricemia Research
Mechanistic level | Key indicators | Common models | Interpretation focus |
Increased purine substrates | Hypoxanthine, xanthine, uric acid | Purine loading, cell damage, metabolic stress | Determine whether upstream substrate supply is enhanced |
Enhanced uric acid production | XO/XDH activity, uric acid production rate | Hepatocytes, liver tissue, enzyme reaction system | Distinguish enzyme activity changes from substrate changes |
Reduced uric acid excretion | Urinary uric acid, uric acid clearance, URAT1, GLUT9, ABCG2 | Kidney model, transporter cell model | Determine changes in reabsorption, secretion, and efflux |
Crystal formation | MSU crystals, crystal morphology, local pH | In vitro crystallization model, joint inflammation model | Distinguish dissolved uric acid from crystalline uric acid |
Inflammatory amplification | NLRP3, Caspase-1, IL-1β, TNF-α | Macrophages, synovial cells, animal inflammation model | Determine the strength of crystal-induced inflammation |
4 Detection Methods and Experimental Design
4.1 Detection of Uric Acid and Purine Metabolites
(1) Uricase method
The uricase method is commonly used to detect uric acid in serum, urine, tissue homogenates, and cell culture supernatants. Uric acid is oxidized by uricase to generate products that can be further coupled to color development, making the method suitable for routine batch detection. Reducing substances, strong pigments, hemolysis, or high-lipid backgrounds in samples may affect colorimetric readings; sample blanks and spike recovery should therefore be included.
(2) HPLC and LC-MS/MS
HPLC can simultaneously analyze uric acid, xanthine, hypoxanthine, and other purine metabolites, making it suitable for pathway-level research. LC-MS/MS offers higher sensitivity and specificity and is suitable for low-abundance metabolites, complex matrices, and isotope tracing experiments. If the research focus is metabolic flux, chromatographic or mass spectrometric methods provide stronger interpretive value than a single uricase assay.
4.2 Detection of Enzyme Activity and Transport Function
(1) Xanthine oxidase activity
XO activity can be detected through uric acid generation, superoxide anion generation, or specific substrate reactions. If the sample already contains high background levels of uric acid or xanthine, no-substrate blanks and heat-inactivated controls should be included to exclude interference from endogenous metabolites.
(2) Transporter detection
Uric acid transport studies can detect proteins or mRNA of URAT1, GLUT9, ABCG2, OAT1/OAT3, and related transporters, or conduct uric acid uptake and efflux assays. Expression changes do not necessarily equal functional changes, especially when membrane localization, transporter substrate competition, or cell polarity changes are involved. Functional assays should be combined for interpretation.
Table 4 Common Detection Indicators in Purine Metabolism and Hyperuricemia Research
Detection indicator | Sample type | Main use | Notes |
Uric acid | Serum, urine, supernatant, tissue | Hyperuricemia status and uric acid production endpoint | Pay attention to hemolysis, pigments, and sample storage |
Hypoxanthine | Serum, cells, tissue | Determine upstream substrate changes in purine degradation | Suitable for HPLC or LC-MS/MS |
Xanthine | Serum, cells, tissue | Evaluate XO substrate accumulation and pathway blockage | Should be analyzed together with uric acid |
XO/XDH activity | Liver tissue, cells, enzyme reaction liquid | Determine enzyme activity changes at the uric acid production end | Set substrate blanks and heat-inactivated controls |
Urinary uric acid/creatinine | Urine | Assess uric acid excretion status | Random urine samples require creatinine correction |
URAT1/GLUT9 | Renal tubular cells, kidney tissue | Evaluate changes related to uric acid reabsorption | Expression and function should be distinguished |
ABCG2 | Intestine, kidney, transporter cells | Evaluate uric acid efflux capacity | Should be combined with transport assays |
IL-1β/NLRP3 | Macrophages, inflammatory tissue | Determine urate crystal-induced inflammation | MSU crystal status must be controlled |
5 Experimental Models and Result Interpretation
5.1 Cell Models
Hepatocytes are suitable for studying changes at the uric acid production end. Renal tubular epithelial cells and transporter-expressing cells are suitable for studying uric acid transport. Macrophages are suitable for studying monosodium urate crystal-induced inflammation. Different cell models answer different questions, and a single model should not be used to explain the entire process of uric acid production, excretion, and crystal inflammation.
5.2 Animal Models
Hyperuricemia animal models are often established by inhibiting uric acid degradation, increasing purine load, or altering uric acid excretion. Because most experimental animals possess uricase, their uric acid metabolism differs from that of humans. Therefore, model design should clearly define whether the focus is uric acid production, uric acid excretion, or urate crystal inflammation. Result interpretation should simultaneously consider serum uric acid, urinary uric acid, renal function indicators, liver XO activity, and renal transporter expression.
5.3 Interpretation of Mechanistic Interventions
XO inhibitors such as allopurinol and febuxostat are often used to verify mechanisms at the uric acid production end. Benzbromarone and probenecid can be used as tools for uric acid transport-related research. Uricase can be used to degrade uric acid and observe downstream effects. When such compounds are used for mechanistic validation, dosage, treatment time, cytotoxicity, and off-target effects should be considered, and experimental results should not be directly equated with clinical medication conclusions.
6 Products Related to Purine Metabolism and Hyperuricemia Research
Table 5 Detection Products, Enzymes, and Regulatory Tools Related to Purine Metabolism Disorders and Hyperuricemia Research
Cat. No. | Product Name | Grade/Specification | Product Category | Application Positioning |
Uric Acid (UA) Content Assay Kit (Uricase, Micro Method) | BioReagent | Uric acid detection product | Used for micro-scale detection of uric acid content in serum, urine, cell supernatant, or tissue homogenate | |
Uric Acid (UA) Content Assay Kit (Uricase, Colorimetric Method) | BioReagent | Uric acid detection product | Used for colorimetric detection of hyperuricemia models, drug intervention, and uric acid production endpoints | |
Uricase (UAO) | Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,≥80%(SDS-PAGE),expressed in E.coli; 8-12 U/mg enzyme powder | Uric acid-degrading enzyme | Used for uricase-based detection, uric acid degradation reactions, and validation of uric acid standard systems | |
Uricase (UAO) from Candida sp. | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,≥4U/mg enzyme powder | Natural uricase | Used for uric acid degradation, uricase-based detection, and enzyme source comparison | |
Uricase from Candida utilis | EnzymoPure™, ≥2 units/mg dry weight | Uric acid-degrading enzyme | Used for uric acid degradation systems, uricase reaction optimization, and detection method development | |
Uricase (UA) | Bioactive, ActiBioPure™, High Performance, EnzymoPure™, ≥90%(SDS-PAGE), ≥20 U/mg powder | High-purity uricase | Used for uric acid quantitative detection, uric acid degradation experiments, and enzyme activity system construction | |
Xanthine Oxidase (XOD) | Bioactive,ActiBioPure™,High Performance,EnzymoPure™,Recombinant,≥50 U/mg protein | Uric acid-producing enzyme | Used for conversion of xanthine to uric acid, XOD inhibitor screening, and uric acid production model construction | |
Xanthine Oxidase Activity Assay Kit (WST-8, Micro Method) | BioReagent | XOD activity detection product | Used for XOD activity detection in liver tissue, cells, or enzyme reaction systems to evaluate changes at the uric acid production end | |
Xanthine Oxidase (XOD) Activity Assay Kit (WST-1, Microscale Method) | BioReagent, Suitable for Analysis, Colorimetry | XOD activity detection product | Used for XOD activity detection in micro systems, suitable for uric acid-lowering interventions and enzyme inhibition experiments | |
Rat Xanthine Oxidase(XOD) ELISA Kit | BioReagent | XOD protein detection product | Used to detect XOD levels in rat models and assist in evaluating changes at the uric acid production end | |
Mouse Xanthine Oxidase (XOD) ELISA Kit | BioReagent | XOD protein detection product | Used to detect XOD protein levels in mouse hyperuricemia models | |
Recombinant Bovine XDH Protein | ≥90%(SDS-PAGE) | Xanthine dehydrogenase protein | Used for XDH/XOD redox state research, enzymatic controls, and method development | |
Recombinant Mouse XDH Protein | ≥90%(SDS-PAGE) | Xanthine dehydrogenase protein | Used for mouse-derived XDH mechanism research and enzymatic validation | |
Human Xanthine Dehydrogenase (XDH) ELISA Kit | BioReagent | XDH detection product | Used to detect XDH levels in human samples and assist in analyzing xanthine oxidoreductase status | |
Rat Xanthine Dehydrogenase (XDH) ELISA Kit | BioReagent | XDH detection product | Used to detect XDH levels in rat models and interpret jointly with XOD activity | |
Monkey Xanthine Dehydrogenase (XDH) ELISA Kit | BioReagent | XDH detection product | Used for XDH detection in monkey-derived samples and purine metabolism research | |
Human Adenosine Deaminase (ADA) ELISA Kit | BioReagent | ADA protein detection product | Used to detect adenosine deaminase levels and analyze upstream purine degradation changes related to adenosine-to-inosine conversion | |
Adenosine Aminohydrolase (ADA) | ActiBioPure™, Bioactive, High Performance, EnzymoPure™, ≥150 U/mg protein | Purine metabolism enzyme | Used for adenosine deamination reactions, purine degradation pathway research, and ADA activity system development | |
Adenosine Deaminase (ADA) Activity Assay Kit (Berthelot, Micro Method) | BioReagent | ADA activity detection product | Used for micro-scale evaluation of ADA activity and upstream purine degradation changes | |
Adenosine Deaminase (ADA) Activity Assay Kit (Berthelot, Colorimetric Method) | BioReagent | ADA activity detection product | Used for colorimetric detection of ADA activity and auxiliary analysis of adenosine metabolism abnormalities | |
Recombinant Human URAT1 Protein | ≥90%(SDS-PAGE) | Uric acid transporter | Used for URAT1-related uric acid reabsorption mechanisms, antibody evaluation, and transport research | |
Mouse Urate Transporter 1(URAT1) ELISA Kit | BioReagent | URAT1 detection product | Used to detect URAT1 levels in mouse kidney or related samples and evaluate changes in uric acid reabsorption | |
Mouse Glucose Transporter 9(GLUT9) ELISA Kit | BioReagent | GLUT9 detection product | Used to detect GLUT9 in mouse models and analyze uric acid transmembrane transport and excretion-side abnormalities | |
Recombinant ABCG2 Antibody | KD Validation | ABCG2 antibody | Used to detect ABCG2/BCRP expression and evaluate uric acid efflux and intestinal/renal excretion mechanisms | |
Recombinant BCRP/ABCG2 Antibody | Recombinant, ExactAb™, Validated, See COA | ABCG2 antibody | Used for ABCG2 protein detection, immunoblotting, or cellular transport model analysis | |
Recombinant BCRP/ABCG2 Antibody | See COA | ABCG2 antibody | Used to verify expression of the uric acid efflux transporter ABCG2 | |
Human ATP Binding Cassette Transporter G2 (ABCG2) ELISA Kit | BioReagent | ABCG2 detection product | Used to detect ABCG2 levels in human samples and assist in evaluating uric acid efflux capacity | |
OAT1/3-IN-1 |
| OAT1/OAT3 transport inhibitor | Used to study organic anion transport, uric acid secretion-end mechanisms, and transporter inhibition effects | |
OAT1/3-IN-2 |
| OAT1/OAT3 transport inhibitor | Used to validate OAT1/OAT3-related uric acid or organic anion transport functions | |
Febuxostat | Moligand™, ≥98% | XOD inhibitor | Used as a positive control for XOD inhibition, uric acid production blockade, and uric acid-lowering mechanism research | |
Febuxostat | Moligand™, 10mM in DMSO | XOD inhibitor solution | Used for XOD inhibition, uric acid production reduction, and pharmacological mechanism validation in cell experiments | |
Probenecid | Moligand™, ≥98% | Uric acid transport research tool | Used for organic anion transport, uric acid excretion mechanisms, and transport inhibition studies | |
Probenecid | Moligand™, 10mM in DMSO | Uric acid transport research tool solution | Used for cellular transport experiments and uric acid excretion-end intervention studies | |
Benzbromarone | analytical standard | URAT1-related research tool | Used for uric acid reabsorption mechanisms, URAT1-related pathways, and methodological controls | |
Benzbromarone | ≥98%(HPLC) | Uric acid transport research tool | Used for uric acid transport intervention and excretion-end mechanism validation | |
Benzbromarone | 10mM in DMSO | Uric acid transport research tool solution | Used for cellular uric acid transport experiments and intervention treatments | |
Uric acid sodium salt | Na 11-13(%) | Urate model material | Used for monosodium urate-related models, urate crystal preparation, and crystal inflammation research | |
Monosodium urate (PBS solution) | 2 wt％ | Urate model material | Used for urate stimulation, MSU-related model pretreatment, or crystal inflammation experiments | |
Recombinant Human NLRP3 Protein | Carrier Free,His Tag,≥90%(SDS-PAGE) | Inflammasome-related protein | Used for NLRP3 inflammasome mechanism research and detection system development | |
Human NLR Family, Pyrin Domain Containing Protein 3 (NALP3/NLRP3) ELISA Kit | BioReagent | NLRP3 detection product | Used to detect NLRP3 levels in human samples and evaluate urate crystal-induced inflammasome activation | |
Rat NLR Family, Pyrin Domain Containing Protein 3 (NLRP3) ELISA Kit | BioReagent | NLRP3 detection product | Used to detect NLRP3 in rat gouty inflammation or hyperuricemia inflammation models | |
Mouse NLR Family, Pyrin Domain Containing Protein 3 (NLRP3) ELISA Kit | BioReagent | NLRP3 detection product | Used to detect NLRP3 levels in mouse MSU crystal inflammation models | |
Caspase-1 Mouse mAb | Carrier Free,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),1.0 mg/mL | Caspase-1 antibody | Used to detect Caspase-1 activation and evaluate MSU crystal-induced inflammasome effects | |
Recombinant Caspase-1 Antibody | Recombinant, ExactAb™, Validated, See COA | Caspase-1 antibody | Used for Caspase-1 expression or activation detection in urate crystal inflammation models | |
Recombinant Human Caspase-1 Protein | ≥90%(SDS-PAGE) | Caspase-1 protein | Used for inflammasome pathway research, antibody evaluation, and detection system development | |
Creatinine (Cr) Content Assay Kit (PA Rate, Micro Method) | BioReagent | Urine correction detection product | Used for urinary uric acid/creatinine correction in random urine samples and renal function-related evaluation | |
Creatinine (Cr) Content Assay Kit (SOX, Micro Method) | BioReagent | Creatinine detection product | Used for micro-scale creatinine detection and auxiliary evaluation of uric acid excretion and renal function | |
Creatinine (Cr) Content Assay Kit (SOX, Colorimetric Method) | BioReagent | Creatinine detection product | Used for colorimetric creatinine detection and calculation of uric acid/creatinine ratios | |
Reactive Oxygen Species Assay Kit |
| Oxidative stress detection product | Used to evaluate oxidative stress related to increased XOD activity or hyperuricemia | |
Mitochondrial Reactive Oxygen Species (ROS) Production Rate Assay Kit (Fluorometric Method) | BioReagent | Mitochondrial ROS detection product | Used to analyze mitochondrial oxidative stress related to hyperuricemia or XOD reactions | |
Malondialdehyde (MDA) Content Assay Kit (TBA, Colorimetric Method) | BioReagent | Lipid peroxidation detection product | Used to evaluate lipid peroxidation levels related to hyperuricemia or urate inflammation | |
Malondialdehyde (MDA) Content Assay Kit (TBA, Fluorometric Method) | BioReagent | Lipid peroxidation detection product | Used for MDA detection in low-content or microscale samples and auxiliary evaluation of oxidative damage | |
Malondialdehyde (MDA) ELISA Kit | BioReagent | MDA detection product | Used to detect MDA levels in samples and evaluate hyperuricemia-related oxidative stress | |
Rat Malondialdehyde(MDA) ELISA Kit | BioReagent | Rat MDA detection product | Used for lipid peroxidation detection in rat hyperuricemia or kidney injury models | |
Lipid Peroxidation (MDA) Assay Kit | sufficient for 100colorimetricorfluorometrictests | Lipid oxidation detection product | Used to detect lipid oxidation levels and assist in analyzing hyperuricemia-related oxidative damage | |
Human Glutathione Peroxidase (GSH-Px) ELISA Kit | BioReagent | Antioxidant enzyme detection product | Used to detect GSH-Px levels in human samples and evaluate antioxidant defense status | |
Mouse Glutathione Peroxidase(GSH-Px) ELISA Kit | BioReagent | Antioxidant enzyme detection product | Used to detect antioxidant enzyme levels in mouse hyperuricemia models | |
Glutathione Peroxidase (GSH-Px) Activity Assay Kit (DTNB, Micro Method) | BioReagent | GSH-Px activity detection product | Used for micro-scale evaluation of antioxidant enzyme activity and oxidative stress defense | |
Glutathione Peroxidase (GSH-Px) Activity Assay Kit (DTNB, Colorimetric Method) | BioReagent | GSH-Px activity detection product | Used for colorimetric detection of GSH-Px activity and auxiliary evaluation of hyperuricemia-related oxidative damage | |
Total Glutathione (T-GSH) Content Assay Kit (DTNB, Micro Method) | BioReagent | Glutathione detection product | Used to evaluate total glutathione level and cellular redox reserve | |
Reduced Glutathione (GSH) Content Assay Kit (DTNB, Micro Method) | BioReagent | GSH detection product | Used for micro-scale detection of reduced glutathione and evaluation of antioxidant capacity | |
Reduced Glutathione (GSH) Content Assay Kit (DTNB, Colorimetric Method) | BioReagent | GSH detection product | Used for colorimetric detection of GSH levels and analysis of hyperuricemia-related redox status | |
Oxidized Glutathione (GSSG) Content Assay Kit (DTNB, Micro Method) | BioReagent | GSSG detection product | Used to detect oxidized glutathione and evaluate oxidative stress degree | |
Oxidized Glutathione (GSSG) Content Assay Kit (DTNB, Colorimetric Method) | BioReagent | GSSG detection product | Used for colorimetric GSSG detection and analysis of GSH/GSSG redox status |
7 Common Questions
7.1 Is measuring only uric acid enough for purine metabolism disorder research?
No. Uric acid is an endpoint indicator and only reflects outcome changes. To determine mechanisms, hypoxanthine, xanthine, XO/XDH activity, uric acid excretion indicators, and related transporters should also be detected.
7.2 Does increased xanthine oxidase activity necessarily cause hyperuricemia?
Not necessarily. Increased XO activity promotes uric acid production, but blood uric acid levels are also affected by uric acid excretion, renal function, intestinal efflux, and sample status. The production end and excretion end should be validated separately.
7.3 What is the difference between a hyperuricemia model and a urate crystal inflammation model?
A hyperuricemia model emphasizes elevated uric acid concentration and metabolic abnormalities, while a urate crystal inflammation model emphasizes MSU crystal stimulation of immune cells and induction of inflammatory responses. The two are related but cannot replace each other.
7.4 What are common interferences in uricase-based uric acid detection?
Hemolysis, lipemia, strongly pigmented samples, reducing substances, and improper sample storage may all affect colorimetric readings. For complex samples, sample blanks and spike recovery are recommended, and HPLC or LC-MS/MS can be used for confirmation when necessary.
7.5 Why should transporters be considered when studying uric acid excretion?
Elevated blood uric acid may result from increased production or reduced excretion. URAT1, GLUT9, ABCG2, and OAT transporters affect uric acid reabsorption, secretion, and efflux, making them important indicators for interpreting excretion-side abnormalities.
Purine metabolism disorders and hyperuricemia research should follow the experimental logic of “substrate source—uric acid production—uric acid excretion—crystal inflammation.” Uric acid detection is suitable for judging endpoint changes, while xanthine oxidase activity, purine intermediates, and uric acid transport indicators further explain mechanisms. If urate crystals are involved, crystal morphology and inflammatory responses should be analyzed separately.
危险品化学品经营许可证（带存储）